Second-Revision ISS (R2-ISS) for multiple myeloma
Second-Revision ISS (R2-ISS) for multiple myeloma - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
Open the Second-Revision ISS (R2-ISS) for multiple myeloma → Runs in your browser. No signup, no tracking.
What this is
Second-Revision ISS (R2-ISS) for multiple myeloma is one of 230 deterministic tools in Sophie Well's Clinical Scoring & Risk group. Second-Revision ISS (R2-ISS) for multiple myeloma - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
When to use it
Use this tool when you need a quick, citable reference. Every calculation runs entirely in your browser - no inputs leave your device, no account is required, no AI is involved. The site enforces a strict Content Security Policy and ships no analytics or third-party CDN.
References
D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within HARMONY. J Clin Oncol. 2022;40(29):3406-3418. Read the source ↗
Worked example: R2-ISS additive score 3 of 5 -- stratum IV (high); median overall survival ~38 months.
Sophie Well is a reference and educational tool. Not medical, legal, or financial advice. Does not replace clinician judgment, professional billing review, or legal counsel.